Boston Scientific Faces Recall and Restructuring Amid Key Product Slowdown

Boston Scientific has recalled a stroke prevention catheter after reports of tip separation, while also announcing a restructuring plan with up to $800 million in charges due to slowing key product lines.

This article was drafted with AI assistance from multiple sources and was reviewed and approved by a human editor before publication.

Boston Scientific is grappling with twin pressures this week: a product recall following reports of catheter tip separation during use, and a major restructuring that could incur up to $800 million in charges.

The company removed a stroke prevention catheter from the market after receiving reports that the device's tip could separate during procedures. The catheter was part of Boston Scientific's portfolio through its acquisition of Silk Road Medical.

Separately, Boston Scientific announced a restructuring plan that involves transferring production lines and cutting jobs. The company expects to take charges of up to $800 million related to the restructuring. The move comes as two of Boston Scientific's key product lines experience a slowdown in growth.

The recall and restructuring underscore challenges facing the medical device maker as it navigates operational and regulatory hurdles while trying to maintain momentum in its core businesses.